Cargando…

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status

Background: Breast cancer bone metastasis (BCBM)-specific genes have been reported without considering biological differences based on estrogen receptor (ER) status. The aims of this study were to identify BCBM-specific genes using our patient dataset and validate previously reported BCBM-specific g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayashi, Naoki, Iwamoto, Takayuki, Qi, Yuan, Niikura, Naoki, Santarpia, Libero, Yamauchi, Hideko, Nakamura, Seigo, Hortobagyi, Gabriel N., Pusztai, Lajos, Symmans, W. Fraser, Ueno, Naoto T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436258/ https://www.ncbi.nlm.nih.gov/pubmed/28529618 http://dx.doi.org/10.7150/jca.13690

Ejemplares similares

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
por: Bianchini, Giampaolo, et al.
Publicado: (2013)

Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems
por: Hess, Kenneth R, et al.
Publicado: (2011)

Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis
por: Niikura, Naoki, et al.
Publicado: (2011)

Evaluation of biological pathways involved in chemotherapy response in breast cancer
por: Tordai, Attila, et al.
Publicado: (2008)

Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient
por: Torikoshi, Yasuhiro, et al.
Publicado: (2013)

Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer
por: McGovern, Susan L, et al.
Publicado: (2012)

Ink4a/Arf(−/−) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(−) quiescent cells
por: Kai, Kazuharu, et al.
Publicado: (2013)

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
por: Masuda, Hiroko, et al.
Publicado: (2013)

Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan
por: Yamauchi, Hideko, et al.
Publicado: (2014)

Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
por: Iwamoto, Takayuki, et al.
Publicado: (2010)

The Role of (18)F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer
por: Niikura, Naoki, et al.
Publicado: (2010)

Fingerprinting Lymph Node Metastases
por: Symmans, W. Fraser, et al.
Publicado: (2008)

The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data
por: Wang, Jing, et al.
Publicado: (2009)

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
por: Esteva, Francisco J, et al.
Publicado: (2007)

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005
por: Anan, Keisei, et al.
Publicado: (2015)

Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006
por: Iwamoto, Takayuki, et al.
Publicado: (2015)

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004
por: Kinoshita, Takayuki, et al.
Publicado: (2015)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry
por: Kawai, Masaaki, et al.
Publicado: (2016)

Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer
por: Bottai, Giulia, et al.
Publicado: (2017)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor–Positive Breast Cancer
por: Fuentes-Mattei, Enrique, et al.
Publicado: (2014)

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
por: Liedtke, Cornelia, et al.
Publicado: (2008)

Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry
por: Iwamoto, Takayuki, et al.
Publicado: (2016)

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry
por: Kataoka, Akemi, et al.
Publicado: (2016)

Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments
por: Qi, Yuan, et al.
Publicado: (2015)

Malignant phyllodes tumor metastasized to the right ventricle: a case report
por: Yoshidaya, Fumi, et al.
Publicado: (2015)

Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile
por: Zhao, Chen, et al.
Publicado: (2011)

Bayesian Mixture Models for Assessment of Gene Differential Behaviour and Prediction of pCR through the Integration of Copy Number and Gene Expression Data
por: Trentini, Filippo, et al.
Publicado: (2013)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
por: Nakatsukasa, Katsuhiko, et al.
Publicado: (2021)

Maximizing biomarker discovery by minimizing gene signatures
por: Chang, Chang, et al.
Publicado: (2011)

A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy
por: Shen, Kui, et al.
Publicado: (2012)

Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
por: Popovici, Vlad, et al.
Publicado: (2010)

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
por: Niikura, Naoki, et al.
Publicado: (2019)

Characterization of DNA variants in the human kinome in breast cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
por: Marczyk, Michal, et al.
Publicado: (2019)

Gene Expression Profiling in Early Breast Cancer—Patient Stratification Based on Molecular and Tumor Microenvironment Features
por: Munkácsy, Gyöngyi, et al.
Publicado: (2022)

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Munkácsy, Gyöngyi, et al.
Publicado: (2023)

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
por: Li, Qiyuan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kd1c0d4hamkr4a7rb09v8hj3es